National Center on Minority Health and Health Disparities; Notice of Closed Meeting, 34694 [07-3080]
Download as PDF
<![CDATA[
34694
Federal Register / Vol. 72, No. 121 / Monday, June 25, 2007 / Notices
sroberts on PROD1PC70 with NOTICES
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Zscan4: A Gene Critical for Early
Embryonic Development
Description of Technology: Activation
of transcription from the embryonic
genome, known as zygotic genome
activation (ZGA), marks the key switch
from maternal to embryonic control of
development and establishes gene
expression patterns required for
continued development of the embryo.
Genes expressed during ZGA may be
important for assisted reproductive
technologies, and in stem cell research
and development.
The inventors have identified Zscan4,
a gene expressed solely in late 2-cell
stage embryos and in embryonic stem
cells. Inhibition of Zscan4 expression
using siRNA techniques delays
progression from the 2-cell stage to the
4-cell stage, and produces blastocysts
that fail to implant in the mouse
embryo. Thus, Zscan4 plays an essential
role in early embryonic development,
with potential applications for the
development of stem cell therapeutics.
The invention discloses methods of
promoting blastocyst outgrowth of
embryonic stem cells. Also disclosed are
Zscan4 expression vectors and methods
of identifying a subpopulation of stem
cells expressing Zscan4.
Applications: Development of stem
cell therapeutics; Assisted reproduction
technologies and studies of early
embryonic development.
Market: State and federal funding for
stem cell research is predicted to reach
$10 billion by 2018.
Development Status: Early stage.
Inventors: Minoru S. Ko et al. (NIA).
Publications: Geppino Falco et al.
Zscan4: A novel gene expressed
exclusively in late 2-cell embryos and
embryonic stem cells. Dev Biol., in
press.
Patent Status: U.S. Provisional
Application No. 60/920,215 filed 26 Mar
2007 (HHS Reference No. E–088–2007/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Tara L. Kirby,
Ph.D.; 301/435–4426;
tarak@mail.nih.gov.
Retrovirus Packaging Cell Lines Based
on Gibbon Ape Leukemia Virus
Description of Technology: Gene
therapy and gene transfer have recently
VerDate Aug<31>2005
23:08 Jun 22, 2007
Jkt 211001
been recognized as effective therapeutic
tools to combat diseases. Accordingly,
market demands for vectors and carriers
to facilitate such interventions have
surged in recent years. Retroviral
vectors provide an efficient and safe
means of gene transfer to eukaryotic
cells. The present invention relates to
genetic engineering involving retrovirus
packaging cells that produce retroviral
vectors. Specifically, the invention
involves the expression plasmids
encoding the envelope glycoproteins of
a family of primate type C retrovirus,
namely, the Gibbon Ape leukemia virus
(GALV). Recombinant vectors derived
from murine leukemia virus (MLV) have
been widely used to introduce genes in
human gene therapy clinical trials. A
key determinant for their use in clinical
gene therapy is the availability of
packaging cell lines capable of
producing large amounts of virus with
identical titers. The present invention
describes the packaging cell lines that
produce MLV-based gene transfer
vectors with the envelope from gibbon
ape leukemia virus. Retroviral vectors
produced are of high titer and have an
expanded host range providing a means
for gene transfer to a wide range of
animal species. The gene transfer
vectors produced are non-infectious and
there was no evidence of production of
helper virus, making these vectors safe.
These cell lines are critical for
producing large amounts of
standardized vector necessary for
efficient in vivo and ex vivo gene
transfer. Therefore, this invention has a
significant commercial application as a
tool in the development of diagnostic
and therapeutic interventions related to
gene transfer and gene therapy.
Inventors: Maribeth V. Eiden (NIMH)
et al.
Patent Status: U.S. Patent No.
5,470,726 issued 28 Nov 1995 (HHS
Reference No. E–201–1991/0–US–02).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Tara L. Kirby,
Ph.D.; 301/435–4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Mental Health,
Laboratory of Cellular and Molecular
Regulation, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the Gibbon Ape
leukemia virus (GALV) packaging cell
line. Please contact Suzanne Winfield at
winfiels@mail.nih.gov for more
information.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Dated: June 14, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–12174 Filed 6–22–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center on Minority Health and
Health Disparities; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center
on Minority Health and Health
Disparities Special Emphasis Panel;
NCMHD Conference Grant Application.
Date: July 19, 2007.
Time: 8 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Two Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Robert Nettey, MD,
Scientific Review Administrator,
National Institute on Minority Health,
and Health Disparities, 6707 Democracy
Blvd., Suite 800, Bethesda, MD 20892,
301–496–3996.
Dated: June 15, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–3080 Filed 6–22–07; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\25JNN1.SGM
25JNN1
]]>Agencies
[Federal Register Volume 72, Number 121 (Monday, June 25, 2007)]
[Notices]
[Page 34694]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-3080]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center on Minority Health and Health Disparities; Notice
of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center on Minority Health and Health
Disparities Special Emphasis Panel; NCMHD Conference Grant Application.
Date: July 19, 2007.
Time: 8 a.m. to 11 a.m.
Agenda: To review and evaluate grant applications and/or proposals.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Robert Nettey, MD, Scientific Review Administrator,
National Institute on Minority Health, and Health Disparities, 6707
Democracy Blvd., Suite 800, Bethesda, MD 20892, 301-496-3996.
Dated: June 15, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-3080 Filed 6-22-07; 8:45 am]
BILLING CODE 4140-01-M
